Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.

Quantitative proteomics followed by IHC identified and validated potential biomarkers for predicting patient response to therapy. These markers can be used, following larger-scale validation, in combination with routine histological analysis providing vital indications of treatment response.